Recent news & events:
-
799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
1520-P: Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
search:
Follow our blog:
Enter your email address to follow this blog and receive notifications of new posts by email.850-P — 2012: Assessing the Comparative Effectiveness (CE) of Basal-Bolus vs. Premix Insulin Using Continuous Glucose Monitoring (CGM) Summary Measures
Clinical Therapeutics/New Technology – Glucose Monitoring and Sensing Presented on Sunday, June 10, 2012 12:00 PM Author(s): DONALD C..805-P — 2012: Improved Glycemic Control and Variability During Insulin Intensification Improve Patient-Centered Outcomes in Type 1 Diabetes
Psychosocial – Behavioral Medicine Presented on Saturday, June 9, 2012 11:30 AM Author(s): MARCIAA. TESTA, JASVINDER K. GILL, MAXWELL.Recent news & events:
-
799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
1520-P: Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
search:
Follow our blog:
Enter your email address to follow this blog and receive notifications of new posts by email.
In 1987, Phase V Technologies, Inc. was founded by the University of Connecticut Research and Development Corporation and named to signify its mission to extend drug development beyond Phase 1 through Phase 4 endpoints and data collection methods. The term “Phase V®” was trademarked as the “fifth phase” of drug development to signify technological advancements in the collection of direct-from-patient assessments and patient-centered outcomes.
Infomation
- Call us: 1-781-237-7737
- Address: 20 Walnut Street, Suite 110, Wellesley Hills, MA 02481
- Need Help: phasev@phasevtechnologiesinc.com
- work time: Mon - Fri : 9.00 am - 5.00 pm
Newsletter
Keep up to date with news from UNSNEC Business. A once a week email with no spam.Recent Posts
Copyright © UNSNEC 2019. All Right Reserved